[약업신문]Daewon Pharmaceutical and Boryeong Pharmaceutical signed a joint promotion contract for two types of Kanab Family

Daewon Pharmaceutical (CEO Seung-Yeol Baek) signed a joint promotion contract with Boryeong Pharmaceutical (CEO Ahn Jae-Hyun and Lee Sam-Soo) on the 23rd for a new drug for treating hypertension,’Kannab Family (Akab, Tubero)’.

The two products that will be jointly sold are’Akab’ and’Tubero’, a combination drug of’Kannab’, an existing high blood pressure treatment, plus a treatment for hyperlipidemia, among Boryeong Pharmaceutical’s representative blockbuster new drug’Kannab’ family.

‘Tubero’ is a product that improves the patient’s medication convenience by combining’Pimasartan’, an ingredient of Kanab, a new hypertension drug, and’Rosuvastatin’, an ingredient for treating hyperlipidemia, and was launched in 2016, and’Akab’ is Kanab. It is a new product released this year as a combination of’Atorvastatin’, which is used as a treatment for hyperlipidemia, with the ingredient’pimasartan’. Since many hypertensive patients have hyperlipidemia, the proportion of combination drugs in the hypertension treatment market is constantly increasing.

With this contract, the distribution, sales and marketing of’Tubero’ to all domestic hospitals and clinics will be handled by Daewon Pharmaceutical, while the distribution of’Akave’ is conducted by Daewon Pharmaceutical, and the sales and marketing are jointly conducted by the two companies.

Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical said, “The Kanab Family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model for domestic new drugs.” “Through this cooperation, it goes beyond becoming another success model for collaboration between domestic companies. We look forward to helping more patients improve their quality of life.”

Daewon Pharmaceutical’s Vice Chairman Seung-Yeol Baek said, “Based on Daewon Pharmaceutical’s differentiated marketing capabilities and sales know-how, we will strive to expand the market share of the’Kannab’ brand so that more hypertension and hyperlipidemia patients can benefit from the treatment benefits of the innovative new drug Kanab Family. “We will continue to expand our product portfolio in the area of ​​chronic diseases in the future so that we can contribute to the improvement of public health,” he said.

Meanwhile, according to the drug research institute UBIST, the domestic hypertension/hyperlipidemia combination market is estimated to be about KRW 114.3 billion by the third quarter of this year. The’Kannab’ family recorded a cumulative prescription amount of 94.3 billion won until November of this year, which is a strong breakthrough of 100 billion won this year.